Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Rheum Dis ; 68(8): 1310-5, 2009 Aug.
Article in English | MEDLINE | ID: mdl-18701557

ABSTRACT

BACKGROUND: Mikulicz's disease (MD) has been considered as one manifestation of Sjögren's syndrome (SS). Recently, it has also been considered as an IgG(4)-related disorder. OBJECTIVE: To determine the differences between IgG(4)-related disorders including MD and SS. METHODS: A study was undertaken to investigate patients with MD and IgG(4)-related disorders registered in Japan and to set up provisional criteria for the new clinical entity IgG(4)-positive multiorgan lymphoproliferative syndrome (IgG(4)+MOLPS). The preliminary diagnostic criteria include raised serum levels of IgG(4) (>135 mg/dl) and infiltration of IgG(4)(+) plasma cells in the tissue (IgG(4)+/IgG+ plasma cells >50%) with fibrosis or sclerosis. The clinical features, laboratory data and pathologies of 64 patients with IgG(4)+MOLPS and 31 patients with typical SS were compared. RESULTS: The incidence of xerostomia, xerophthalmia and arthralgia, rheumatoid factor and antinuclear, antiSS-A/Ro and antiSS-B/La antibodies was significantly lower in patients with IgG(4)+MOLPS than in those with typical SS. Allergic rhinitis and autoimmune pancreatitis were significantly more frequent and total IgG, IgG(2), IgG(4) and IgE levels were significantly increased in IgG(4)+MOLPS. Histological specimens from patients with IgG(4)+MOLPS revealed marked IgG(4)+ plasma cell infiltration. Many patients with IgG(4)+MOLPS had lymphocytic follicle formation, but lymphoepithelial lesions were rare. Few IgG(4)+ cells were seen in the tissue of patients with typical SS. Thirty-eight patients with IgG(4)+MOLPS treated with glucocorticoids showed marked clinical improvement. CONCLUSION: Despite similarities in the involved organs, there are considerable clinical and pathological differences between IgG(4)+MOLPS and SS. Based on the clinical features and good response to glucocorticoids, we propose a new clinical entity: IgG(4)+MOLPS.


Subject(s)
Immunoglobulin G/analysis , Lymphoproliferative Disorders/immunology , Mikulicz' Disease/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Diagnosis, Differential , Female , Glucocorticoids/therapeutic use , Humans , Lacrimal Apparatus/pathology , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/drug therapy , Lymphoproliferative Disorders/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Mikulicz' Disease/diagnosis , Mikulicz' Disease/drug therapy , Mikulicz' Disease/pathology , Prednisolone/therapeutic use , Retrospective Studies , Salivary Glands, Minor/pathology , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/immunology , Sjogren's Syndrome/pathology , Syndrome , Young Adult
2.
Lupus ; 17(3): 210-4, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18372362

ABSTRACT

Amegakaryocytic thrombocytopenia is an extremely rare disorder in systemic lupus erythematosus, and its mechanism and treatment are still largely unknown. We describe a 42-year-old woman with systemic lupus erythematosus who presented various clinical manifestations of life-threatening amegakaryocytic thrombocytopenia (10,000 platelets/mm3 with a marked decrease of megakaryocytes in the bone marrow), proteinuria, psychosis, refractory chylothorax, ascites, and type II diabetes caused by the anti-insulin receptor autoantibody. She was initially treated with prednisolone (25-50 mg/day) and cyclosporine A (200 mg/day) without any improvement in severe thrombocytopenia. However, her clinical symptoms, including platelet counts, dramatically improved, with a concurrent decrease in the anti-c-Mpl antibody, an autoantibody against the thrombopoietin receptor, after a subsequent treatment with rituximab (375 mg/m2 intravenously, weekly, for two consecutive weeks). Our case suggested that amegakaryocytic thrombocytopenia in patients with systemic lupus erythematosus might be mediated by the anti-c-Mpl antibody and could be treated with rituximab through elimination of pathogenic B cells producing autoimmune antibodies.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Lupus Erythematosus, Systemic/complications , Megakaryocytes/pathology , Thrombocytopenia/drug therapy , Adult , Antibodies, Monoclonal, Murine-Derived , Antigens, CD20/immunology , Autoantibodies/blood , Blood Platelets/immunology , Female , Humans , Lupus Erythematosus, Systemic/immunology , Receptors, Thrombopoietin/immunology , Rituximab , Thrombocytopenia/etiology
3.
Clin Exp Immunol ; 150(2): 279-84, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17937678

ABSTRACT

The aim of this study was to clarify the nature of the clonal lymphocyte infiltration in Sjögren's syndrome (SS) patients associated with lymphoproliferative disorders. We examined B cell clonality in lymphoproliferative tissues from six primary SS patients associated with lymphoproliferative disorders or lymphoma by cloning and sequencing of the gene rearrangement of the immunoglobulin heavy chain complementarity determining region 3 (IgVH-CDR3). Three patients with sequential observation showed progressional clonal expansion with the presence of the same subclone in different tissues during the course of disease. Among them, one patient developed mucosa-associated lymphoid tissue (MALT) lymphoma in glandular parotid. The other three SS patients concomitant with malignant B cells lymphomas showed different clonal expansion of B cells between nodal sites and salivary glands. The cloanality analysis indicated that monoclonal B cell population could spread from one glandular site to another site during the course of SS, suggesting that the malignant clone may arise from the general abnormal microenvironment, not restricted to the glandular tissue, in some SS patients.


Subject(s)
B-Lymphocytes/pathology , Lymphoproliferative Disorders/pathology , Neoplastic Stem Cells/pathology , Sjogren's Syndrome/pathology , Aged , Aged, 80 and over , Amino Acid Sequence , Complementarity Determining Regions/genetics , Disease Progression , Female , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Humans , Immunoglobulin Heavy Chains/genetics , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Middle Aged , Polymerase Chain Reaction/methods
4.
J Nutr ; 131(11): 2848-52, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11694607

ABSTRACT

According to traditional Chinese belief, oolong tea is effective in the control of body weight. Few controlled studies, however, have been conducted to measure the impact of tea on energy expenditure (EE) of humans. A randomized cross-over design was used to compare 24-h EE of 12 men consuming each of four treatments: 1) water, 2) full-strength tea (daily allotment brewed from 15 g of tea), 3) half-strength tea (brewed from 7.5 g tea) and 4) water containing 270 mg caffeine, equivalent to the concentration in the full-strength tea treatment. Subjects refrained from consuming caffeine or flavonoids for 4 d prior to the study. Tea was brewed each morning; beverages were consumed at room temperature as five 300 mL servings. Subjects received each treatment for 3 d; on the third day, EE was measured by indirect calorimetry in a room calorimeter. For the 3 d, subjects consumed a typical American diet. Energy content of the diet was tailored to each subject's needs as determined from a preliminary measure of 24-h EE by calorimetry. Relative to the water treatment, EE was significantly increased 2.9 and 3.4% for the full-strength tea and caffeinated water treatments, respectively. This increase over water alone represented an additional expenditure of 281 and 331 kJ/d for subjects treated with full-strength tea and caffeinated water, respectively. In addition, fat oxidation was significantly higher (12%) when subjects consumed the full-strength tea rather than water.


Subject(s)
Adipose Tissue/metabolism , Catechin/pharmacology , Energy Metabolism , Oxidation-Reduction/drug effects , Tea , Absorptiometry, Photon , Adipose Tissue/drug effects , Adult , Caffeine/blood , Catechin/isolation & purification , Humans , Male , Middle Aged , Oxygen Consumption
5.
Meat Sci ; 15(2): 77-83, 1985.
Article in English | MEDLINE | ID: mdl-22056126

ABSTRACT

To investigate the influence of connectin (titin) on meat tenderization during conditioning, changes in the content and the electrophoretic pattern of the connectin in chicken myofibrils isolated by gel permeation chromatography were studied. Significant difference of the content and the electrophoretic pattern of the connectin isolated was not observed between the preparations from fresh and stored muscle. Therefore, the connectin is unlikely to be responsible for the meat tenderization caused by conditioning.

SELECTION OF CITATIONS
SEARCH DETAIL
...